<DOC>
	<DOCNO>NCT01291667</DOCNO>
	<brief_summary>Breast cancer common malignant disease frequent cause cancer mortality female worldwide . The situation world China . Trastuzumab prove valuable treatment HER2-positive breast cancer patient . Cipterbin® develop Shanghai CP Guojian Pharmaceutical Co.Ltd.Now carry phase III trial order prove Cipterbin® 's efficacy safety .</brief_summary>
	<brief_title>Study HER2-Overexpressed MBC Patients Treated Cipterbin® Plus vinorelbinE</brief_title>
	<detailed_description />
	<mesh_term>Vinorelbine</mesh_term>
	<criteria>sign ICF pathologic diagnosis breast cancer HER2+ status define IHC3+ Staining situ hybridization positive least 1 measurable lesion per RECIST criterion age 18y 70y KPS &gt; =70 More three prior chemotherapy line advance disease LVEF &lt; 50 % prior exposure vinorebine breast cancer prior exposure Trastuzumab breast cancer uncontrolled brain metastasis breastfeeding pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>